Krabbe disease: Combined therapies for the central and peripheral nervous systems

克拉伯病:中枢和周围神经系统的联合疗法

基本信息

  • 批准号:
    7372397
  • 负责人:
  • 金额:
    $ 30.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1986
  • 资助国家:
    美国
  • 起止时间:
    1986-09-01 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This is a proposal to continue our studies on the treatment of the mouse models of Krabbe disease or globoid cell leukodystrophy (GLD), an autosomal recessive disorder caused by the deficiency of galactocerebrosidase (GALC) activity. GALC is responsible for the lysosomal catabolism of galactosylceramide and psychosine. In GLD, the accumulation of psychosine in the CNS and PNS results in the apoptotic death of myelin-forming cells. Other mechanisms, including activation of resident microglial cells, recruitment of blood macrophages and inflammation, also play important roles in the pathogenesis. The only treatment currently available for some patients is hematopoietic stem cell transplantation (HSCT). While this treatment helps to maintain cognitive abilities, motor function remains a problem. Therapy trials with viral vectors and HSCT in the dog and mouse models have not lead to complete clinical, biochemical and pathological correction. It is clear that combined therapy will be required for entirely successful treatment. Questions related to early pathological changes and timing and dosage of GALC activity remain to be answered. In Aim 1, we will generate transgenic mice that have GALC expression under control of a tetracycline (tet) responsive promoter. Initially, we will produce Tet-Off mice (trG) that will have high GALC expression in the absence of tet analogues. After detailed characterization of these mice, they will be mated with heterozygous GALC-deficient mice to produce mice with no GALC activity except that regulated by tet analogues. The trG mice will be used to answer important questions regarding the timing of treatment and dosage of GALC activity needed for correction, and as a source of stem cells for transplantation. In Aim 2, we will improve upon the outcome of BMT by preparing and testing viral vectors for in vivo and ex vivo therapy trials. We have prepared a high titer lentiviral vector both for raising GALC activity in bone marrow cells for transplantation and for direct intracerebral injection. In addition we will construct a lentiviral vector containing both the mouse GALC gene and a tet responsive element. This vector will be used to transduce mouse BM cells that will have GALC high activity, above the low levels present in untransduced cells from normal donor mice and, in addition, will have the expression of GALC under control of tet analogues. We will determine the ability of GALC-AAV2/1 injected into the hind limb muscles to attain high GALC expression in order to correct the residual motor deficits in mice receiving BMT. Also, intracerebral, intraventricular and intracerebellar injections of mGALC-AAV2/1 will be combined with BMT and approved drugs that could reduce inflammation and prevent apoptosis. Initially these drugs will include minocycline and Indomethacin. These drugs have been successful in reducing demyelination and in providing neuroprotection in other neurodegenerative disorders. Studies using the dog model of GLD have been dropped from this application. Krabbe disease a genetic disease affecting mostly infants. Treatment options are limited at this time, but the studies proposed in animal models could lead the way to improved therapies for human patients. A combination of therapies may be needed to both stop the pathological events and provide long-term correction.
描述(由申请方提供):这是一项继续研究克拉伯病或球样细胞脑白质营养不良(GLD)小鼠模型治疗的建议,GLD是一种由半乳糖苷酶(GALC)活性缺乏引起的常染色体隐性遗传疾病。GALC负责半乳糖神经酰胺和精神病的溶酶体催化。在GLD中,CNS和PNS中精神病碱的积累导致髓鞘形成细胞的凋亡性死亡。其他机制,包括激活驻留的小胶质细胞,募集血液巨噬细胞和炎症,也发挥重要作用的发病机制。目前对某些患者可用的唯一治疗方法是造血干细胞移植(HSCT)。虽然这种治疗有助于维持认知能力,但运动功能仍然是一个问题。在狗和小鼠模型中使用病毒载体和HSCT的治疗试验尚未导致完全的临床、生化和病理纠正。很明显,要完全成功地治疗,需要联合治疗。有关早期病理变化和GALC活性的时间和剂量的问题仍有待回答。在目标1中,我们将产生在四环素(泰特)响应性启动子控制下具有GALC表达的转基因小鼠。最初,我们将产生Tet-Off小鼠(trG),其在不存在泰特类似物的情况下具有高GALC表达。在对这些小鼠进行详细表征后,将其与杂合GALC缺陷小鼠交配,以产生除泰特类似物调节外无GALC活性的小鼠。trG小鼠将用于回答关于治疗时间和校正所需的GALC活性剂量的重要问题,并作为移植干细胞的来源。在目标2中,我们将通过制备和测试用于体内和离体治疗试验的病毒载体来改善BMT的结果。我们已经制备了一种高滴度的慢病毒载体,用于提高骨髓细胞中GALC的活性,用于移植和直接脑内注射。此外,我们将构建含有小鼠GALC基因和泰特应答元件的慢病毒载体。该载体将用于转染小鼠BM细胞,所述小鼠BM细胞将具有高于来自正常供体小鼠的未转导细胞中存在的低水平的GALC高活性,此外,将具有在泰特类似物控制下的GALC表达。我们将确定注射到后肢肌肉中的GALC-AAV 2/1获得高GALC表达以校正接受BMT的小鼠中的残余运动缺陷的能力。此外,mGALC-AAV 2/1的脑内、脑室内和小脑内注射将与BMT和可减少炎症和防止细胞凋亡的批准药物组合。最初这些药物将包括米诺环素和吲哚美辛。这些药物已成功地减少脱髓鞘,并在其他神经退行性疾病中提供神经保护。使用狗GLD模型的研究已从本申请中删除。 Krabbe病是一种遗传性疾病,主要影响婴儿。目前的治疗选择有限,但在动物模型中提出的研究可能会为人类患者提供更好的治疗方法。可能需要联合治疗来阻止病理事件并提供长期纠正。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A WENGER其他文献

DAVID A WENGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A WENGER', 18)}}的其他基金

GENETIC AND BIOCHEMICAL STUDIES ON KRABBE'S DISEASE
克拉伯病的遗传学和生物化学研究
  • 批准号:
    2140681
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
GENETIC AND BIOCHEMICAL STUDIES ON KRABBE'S DISEASE
克拉伯病的遗传学和生物化学研究
  • 批准号:
    3238306
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
GENETIC AND BIOCHEMICAL STUDIES ON KRABBE DISEASE
克拉伯病的遗传学和生物化学研究
  • 批准号:
    3238305
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
GENETIC AND BIOCHEMICAL STUDIES ON KRABBE'S DISEASE
克拉伯病的遗传学和生物化学研究
  • 批准号:
    3238301
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
Krabbe Disease-Molecular Analysis and Treatment
克拉伯病-分子分析与治疗
  • 批准号:
    6711795
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
Krabbe disease: Combined therapies for the central and peripheral nervous systems
克拉伯病:中枢和周围神经系统的联合疗法
  • 批准号:
    7570708
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
GENETIC AND BIOCHEMICAL STUDIES ON KRABBES DISEASE
克拉布斯病的遗传学和生物化学研究
  • 批准号:
    2469608
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
KRABBE DISEASE--MOLECULAR ANALYSIS AND TREATMENT
克拉伯病--分子分析和治疗
  • 批准号:
    6482244
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
GENETIC AND BIOCHEMICAL STUDIES ON KRABBE'S DISEASE
克拉伯病的遗传学和生物化学研究
  • 批准号:
    2140682
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:
KRABBE DISEASE--MOLECULAR ANALYSIS AND TREATMENT
克拉伯病--分子分析和治疗
  • 批准号:
    2734064
  • 财政年份:
    1986
  • 资助金额:
    $ 30.93万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了